Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-2 antisense therapy in hematologic malignancies.

Asher Chanan-Khan1

  • 1Roswell Park Cancer Institute, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org

Current Opinion in Oncology
|January 1, 2005
PubMed
Summary

Oblimersen, an antisense therapy targeting Bcl-2, shows promise in hematologic malignancies. Early trials indicate potential to overcome chemotherapy resistance and improve patient outcomes, with ongoing studies to confirm clinical utility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same author

Multi-omics analysis reveals a unique epigenetic signature in <i>MYD88</i> wild-type Waldenström macroglobulinemia.

Haematologica·2025
Same author

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Med (New York, N.Y.)·2025
Same author

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.

Journal of managed care & specialty pharmacy·2025
Same author

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.

Leukemia·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Bcl-2 oncoprotein overexpression is linked to poor prognosis and chemotherapy resistance in hematologic malignancies.
  • Bcl-2 represents a critical molecular target for therapeutic intervention.
  • Targeting Bcl-2 may reverse tumor resistance and enhance treatment response.

Purpose of the Study:

  • To review preclinical and clinical data on oblimersen, an antisense molecule targeting Bcl-2.
  • To evaluate the potential of oblimersen in treating malignant hematologic disorders.

Main Methods:

  • Review of preclinical studies on oblimersen.
  • Analysis of Phase I, II, and III clinical trial data for oblimersen in various hematologic cancers.
  • Assessment of oblimersen's efficacy as a single agent and in combination therapy.

Related Experiment Videos

Main Results:

  • Early trials demonstrate single-agent activity of oblimersen in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
  • Phase I/II studies show encouraging results with oblimersen combined with chemotherapy in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.
  • Phase III trials in multiple myeloma and chronic lymphocytic leukemia have completed accrual, with results pending.

Conclusions:

  • Bcl-2 is a clinically significant target in hematologic malignancies.
  • Oblimersen effectively downregulates the Bcl-2 oncoprotein.
  • Early clinical data suggest oblimersen's potential role in treating hematologic malignancies, pending results from ongoing trials.